Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00605/full |
| _version_ | 1818614240125124608 |
|---|---|
| author | Rickinder Sethi Nieves Gómez-Coronado Adam J. Walker Oliver D’Arcy Robertson Oliver D’Arcy Robertson Bruno Agustini Michael Berk Michael Berk Michael Berk Michael Berk Michael Berk Seetal Dodd Seetal Dodd Seetal Dodd Seetal Dodd |
| author_facet | Rickinder Sethi Nieves Gómez-Coronado Adam J. Walker Oliver D’Arcy Robertson Oliver D’Arcy Robertson Bruno Agustini Michael Berk Michael Berk Michael Berk Michael Berk Michael Berk Seetal Dodd Seetal Dodd Seetal Dodd Seetal Dodd |
| author_sort | Rickinder Sethi |
| collection | DOAJ |
| description | Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and inflammation. Consequently, anti-inflammatory agents, such as the cyclooxygenase-2 inhibitors, represent a novel avenue to prevent and treat neuropsychiatric illness. In this paper, we first review the role of inflammation in psychiatric pathophysiology including inflammatory cytokines’ influence on neurotransmitters, the hypothalamic–pituitary–adrenal axis, and microglial mechanisms. We then discuss how cyclooxygenase-2-inhibitors influence these pathways with potential therapeutic benefit, with a focus on celecoxib, due to its superior safety profile. A search was conducted in PubMed, Embase, and PsychINFO databases, in addition to Clinicaltrials.gov and the Stanley Medical Research Institute trial registries. The results were presented as a narrative review. Currently available outcomes for randomized controlled trials up to November 2017 are also discussed. The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication. |
| first_indexed | 2024-12-16T16:14:52Z |
| format | Article |
| id | doaj.art-d73c40ebfea74ded8939f578307f91b8 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-16T16:14:52Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-d73c40ebfea74ded8939f578307f91b82022-12-21T22:25:08ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-09-011010.3389/fpsyt.2019.00605425455Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric DisordersRickinder Sethi0Nieves Gómez-Coronado1Adam J. Walker2Oliver D’Arcy Robertson3Oliver D’Arcy Robertson4Bruno Agustini5Michael Berk6Michael Berk7Michael Berk8Michael Berk9Michael Berk10Seetal Dodd11Seetal Dodd12Seetal Dodd13Seetal Dodd14Department of Psychiatry, Western University, London, ON, CanadaUnidad de Gestión Clinica Salud Mental, Hospital Universitario Virgen del Rocio, Sevilla, SpainIMPACT Strategic Research Centre, Deakin University, Geelong, VIC, AustraliaIMPACT Strategic Research Centre, Deakin University, Geelong, VIC, AustraliaUniversity Hospital Geelong, Barwon Health, Geelong, VIC, AustraliaIMPACT Strategic Research Centre, Deakin University, Geelong, VIC, AustraliaIMPACT Strategic Research Centre, Deakin University, Geelong, VIC, AustraliaUniversity Hospital Geelong, Barwon Health, Geelong, VIC, AustraliaDepartment of Psychiatry, The University of Melbourne, Parkville, VIC, AustraliaOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, AustraliaDepartment of Psychiatry, Florey Institute of Neuroscience and Mental Health, Parkville, VIC, AustraliaIMPACT Strategic Research Centre, Deakin University, Geelong, VIC, AustraliaUniversity Hospital Geelong, Barwon Health, Geelong, VIC, AustraliaDepartment of Psychiatry, The University of Melbourne, Parkville, VIC, AustraliaOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, AustraliaNeuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and inflammation. Consequently, anti-inflammatory agents, such as the cyclooxygenase-2 inhibitors, represent a novel avenue to prevent and treat neuropsychiatric illness. In this paper, we first review the role of inflammation in psychiatric pathophysiology including inflammatory cytokines’ influence on neurotransmitters, the hypothalamic–pituitary–adrenal axis, and microglial mechanisms. We then discuss how cyclooxygenase-2-inhibitors influence these pathways with potential therapeutic benefit, with a focus on celecoxib, due to its superior safety profile. A search was conducted in PubMed, Embase, and PsychINFO databases, in addition to Clinicaltrials.gov and the Stanley Medical Research Institute trial registries. The results were presented as a narrative review. Currently available outcomes for randomized controlled trials up to November 2017 are also discussed. The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00605/fulldepressionbipolar disorderschizophreniaobsessive compulsive disorderautism spectrum disorderpsychiatry |
| spellingShingle | Rickinder Sethi Nieves Gómez-Coronado Adam J. Walker Oliver D’Arcy Robertson Oliver D’Arcy Robertson Bruno Agustini Michael Berk Michael Berk Michael Berk Michael Berk Michael Berk Seetal Dodd Seetal Dodd Seetal Dodd Seetal Dodd Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders Frontiers in Psychiatry depression bipolar disorder schizophrenia obsessive compulsive disorder autism spectrum disorder psychiatry |
| title | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| title_full | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| title_fullStr | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| title_full_unstemmed | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| title_short | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| title_sort | neurobiology and therapeutic potential of cyclooxygenase 2 cox 2 inhibitors for inflammation in neuropsychiatric disorders |
| topic | depression bipolar disorder schizophrenia obsessive compulsive disorder autism spectrum disorder psychiatry |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00605/full |
| work_keys_str_mv | AT rickindersethi neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT nievesgomezcoronado neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT adamjwalker neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT oliverdarcyrobertson neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT oliverdarcyrobertson neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT brunoagustini neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT michaelberk neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT michaelberk neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT michaelberk neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT michaelberk neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT michaelberk neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT seetaldodd neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT seetaldodd neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT seetaldodd neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders AT seetaldodd neurobiologyandtherapeuticpotentialofcyclooxygenase2cox2inhibitorsforinflammationinneuropsychiatricdisorders |